85 results on '"Lebrec J"'
Search Results
2. PDB39 Dosing Patterns Among Patients with Type 2 Diabetes (T2D) Initiating Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAS) in France and the Netherlands
3. Clinical characteristics, treatment patterns and persistence in patients with T2D initiating a Glucagon-like-peptide 1 receptor agonists (GLP-1 RA): a retrospective analysis of the Diabetes Prospective Follow-Up (DPV) registry
4. PDB119 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN TYPE 2 DIABETES MELLITUS (T2DM): DATA FROM A REAL WORLD STUDY IN SPAIN
5. Arthur: software for weighted score tests for linkage analysis
6. Testing for genetic association in the presence of linkage
7. A Polygenic Model for Integration of Linkage and Pathway Information
8. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer
9. Strategy for Pooling Evidence for Linkage from Different Populations
10. An Analytic Study of the Impact of Genotyping Error in Mapping of Complex Traits Using Selected SIB Pairs - Session: Statistical Issues in Twin Studies
11. How useful is the EQ-5D in assessing the impact of caring for people with Alzheimer's disease?
12. PDB110 - TREATMENT PERSISTENCE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH GLP-1 RECEPTOR AGONISTS IN CLINICAL PRACTICE IN SWEDEN: NATIONWIDE RETROSPECTIVE COHORT STUDY
13. PDB112 - TREATMENT AND DOSING PATTERNS AMONG PATIENTS WITH TYPE 2 DIABETES (T2D) INITIATING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) IN SEVERAL COUNTRIES
14. Drug uilization patterns in patients Initiating glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the treatment of type 2 diabetes (T2D) in Germany: A retrospective cohort study
15. Reduction of HbA1c with dulaglutide in type 2 diabetes (T2D) patients negative, low positive or high positive for GAD antibodies (GADA): a post hoc analysis of AWARD -2, -4 and -5
16. Real-world Alzheimer’s disease drug treatment – 18-month results from an observational study in three European countries (GERAS; encore from 2016 EAN)
17. Predictors of Disease Progression in Mild Alzheimer’s Disease Dementia Patients – Results From the Geras Real World Cohort and Expedition Trials
18. Burden of illness and health care resource utilization in adult psychiatric outpatients with attention-deficit/hyperactivity disorder in Europe
19. How Useful are Eq-5d And Zbi In Assessing The Impact of Caring for Alzheimer’s Disease Patients?
20. 51 * COST AND RESOURCE USE IN NON-INSTITUTIONALISED ALZHEIMER'S PATIENTS - RESULTS FROM AN OBSERVATIONAL STUDY IN THE UK OVER 18 MONTHS
21. The Effect of Attention-Deficit/Hyperactivity Disorder on Functioning and Resource Utilization by Psychiatric Outpatients in Europe
22. P.1.k.019 Prevalence of ADHD in non-psychotic adult psychiatric care (ADPSYC): a multinational cross-sectional study in Europe
23. PND5 - Predictors of Disease Progression in Mild Alzheimer’s Disease Dementia Patients – Results From the Geras Real World Cohort and Expedition Trials
24. Effect of everolimus treatment on chromogranin A, neuron-specific enolase, gastrin, and glucagon levels in patients with advanced pancreatic neuroendocrine tumors (pNET): Phase III RADIANT-3 study results.
25. Effect of everolimus plus octreotide LAR treatment on chromogranin A and 5-hydroxyindoleacetic acid levels in patients with advanced neuroendocrine tumors: Phase III RADIANT-2 study results.
26. PMH28 - The Effect of Attention-Deficit/Hyperactivity Disorder on Functioning and Resource Utilization by Psychiatric Outpatients in Europe
27. Potential bias in generalized estimating equations linkage methods under incomplete information
28. Score test for detecting linkage to complex traits in selected samples
29. PND67 - How Useful are Eq-5d And Zbi In Assessing The Impact of Caring for Alzheimer’s Disease Patients?
30. PND67 How Useful are Eq-5d And Zbi In Assessing The Impact of Caring for Alzheimer’s Disease Patients?
31. PMH28 The Effect of Attention-Deficit/Hyperactivity Disorder on Functioning and Resource Utilization by Psychiatric Outpatients in Europe
32. Influence of genotyping error in linkage mapping for complex traits – an analytic study
33. The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy.
34. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.
35. The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical outcomes.
36. Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist: A retrospective analysis of the Diabetes Prospective Follow-Up Registry.
37. Age-dependent prevalence of type 2 diabetes, cardiovascular risk profiles and use of diabetes drugs in Germany using health claims data.
38. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months.
39. Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus: DosInGlar Study.
40. Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain.
41. Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.
42. Treatment persistence in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists in clinical practice in Sweden.
43. Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c.
44. GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data.
45. The Cost of Hypoglycemia Associated With Type 2 Diabetes Mellitus in Taiwan.
46. Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study.
47. Response to the comment on: "Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 trials".
48. Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials.
49. Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study.
50. Potential cost savings to be made by slowing cognitive decline in mild Alzheimer's disease dementia using a model derived from the UK GERAS observational study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.